- Home
- OVID vs RIGL Comparison
OVID vs RIGL Comparison
Compare OVID & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OVID | RIGL |
|---|---|---|
| Founded | 2014 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 522.6M | 564.7M |
| IPO Year | 2017 | 2000 |
Fundamental Metrics
Financial Performance| Metric | OVID | RIGL |
|---|---|---|
| Price | $2.74 | $42.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $4.60 | ★ $45.67 |
| AVG Volume (30 Days) | ★ 3.4M | 339.2K |
| Earning Date | 05-13-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.90 | ★ 1867.68 |
| EPS | N/A | ★ 0.44 |
| Revenue | $7,252,000.00 | ★ $294,282,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $19.34 | $12.75 |
| P/E Ratio | ★ N/A | $91.49 |
| Revenue Growth | ★ 1181.27 | 64.15 |
| 52 Week Low | $0.36 | $18.52 |
| 52 Week High | $3.11 | $52.24 |
Technical Indicators
Market Signals| Indicator | OVID | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 60.23 | 82.77 |
| Support Level | $2.23 | $40.05 |
| Resistance Level | $3.05 | $44.85 |
| Average True Range (ATR) | 0.19 | 1.82 |
| MACD | 0.04 | 0.57 |
| Stochastic Oscillator | 86.05 | 100.00 |
Price Performance
Historical ComparisonAbout OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.